Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus riluzole versus placebo plus riluzole in amyotrophic lateral sclerosis
NL-OMON49977Phase 3Withdrawn
- Sponsor
- AB Science
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of masitinib in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by AB Science. Primary endpoint: Absolute change from baseline of ALSFRS-R total score at week 48. Planned start Sep 2019; status: withdrawn.
02
Drugs
masitinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON49977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49977.